Celldex Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2013
Filed with the SEC on Nov 8, 2013 and accepted by EDGAR at Nov 8, 2013, 09:47 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2013-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2013-07-01 to 2013-09-30 | $980.0k | us-gaap:Revenues |
| Revenue | 9 months2013-01-01 to 2013-09-30 | $3.5m | us-gaap:Revenues |
| Research and development | 3 months2013-07-01 to 2013-09-30 | $20.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2013-01-01 to 2013-09-30 | $49.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2013-07-01 to 2013-09-30 | −$23.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2013-01-01 to 2013-09-30 | −$59.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2013-07-01 to 2013-09-30 | $13.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2013-01-01 to 2013-09-30 | $842.0k | us-gaap:InterestExpense |
| Net income | 3 months2013-07-01 to 2013-09-30 | −$23.1m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 9 months2013-01-01 to 2013-09-30 | −$59.5m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2013-07-01 to 2013-09-30 | −$0.29 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2013-01-01 to 2013-09-30 | −$0.76 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2013-01-01 to 2013-09-30 | −$52.7m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 9 months2013-01-01 to 2013-09-30 | $1.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2013-09-30 | $14.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2013-09-30 | $139.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2013-09-30 | $181.0m | us-gaap:Assets |
| Current liabilities | At period end2013-09-30 | $16.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2013-09-30 | $24.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2013-09-30 | $156.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-13-082619. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.